{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:31:46Z","timestamp":1707525106084},"reference-count":19,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,4,26]]},"DOI":"10.7759\/cureus.38154","type":"journal-article","created":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T15:44:54Z","timestamp":1682523894000},"source":"Crossref","is-referenced-by-count":0,"title":["Aflibercept for the Treatment of Macular Edema Secondary to Idiopathic Retinal Vasculitis, Aneurysms, and Neuroretinitis Syndrome"],"prefix":"10.7759","author":[{"given":"Jos\u00e9","family":"L\u00f3pez Fontanet","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sof\u00eda C","family":"Ayala Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Armando L","family":"Oliver","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.joco.2015.10.006","article-title":"Unilateral idiopathic retinal vasculitis, aneurysms, and neuroretinitis syndrome (IRVAN) in a young female","volume":"27","author":"Moosavi M","year":"2015","unstructured":"Moosavi M, Hosseini SM, Shoeibi N, Ansari-Astaneh MR. Unilateral idiopathic retinal vasculitis, aneurysms, and neuroretinitis syndrome (IRVAN) in a young female. J Curr Ophthalmol. 2015, 27:63-6. 10.1016\/j.joco.2015.10.006","journal-title":"J Curr Ophthalmol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/s0161-6420(95)30907-4","article-title":"Idiopathic retinal vasculitis, aneurysms, and neuro-retinitis. Retinal vasculitis study","volume":"102","author":"Chang TS","year":"1995","unstructured":"Chang TS, Aylward GW, Davis JL, Mieler WF, Oliver GL, Maberley AL, Gass JD. Idiopathic retinal vasculitis, aneurysms, and neuro-retinitis. Retinal vasculitis study. Ophthalmology. 1995, 102:1089-97. 10.1016\/s0161-6420(95)30907-4","journal-title":"Ophthalmology"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1177\/25158414211070880","article-title":"Comprehensive overview of IRVAN syndrome: a structured review of case reports and case series","volume":"14","author":"Ali Khan H","year":"2022","unstructured":"Ali Khan H, Ali Khan Q, Shahzad MA, et al.. Comprehensive overview of IRVAN syndrome: a structured review of case reports and case series. Ther Adv Ophthalmol. 2022, 14:10.1177\/25158414211070880","journal-title":"Ther Adv Ophthalmol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1186\/s12348-016-0074-3","article-title":"Vanishing retinal arterial aneurysms with anti-tubercular treatment in a patient presenting with idiopathic retinal vasculitis, aneurysms, and neuroretinitis","volume":"6","author":"Singh R","year":"2016","unstructured":"Singh R, Sharma K, Agarwal A, Dogra M, Gupta V, Sharma A, Dogra MR. Vanishing retinal arterial aneurysms with anti-tubercular treatment in a patient presenting with idiopathic retinal vasculitis, aneurysms, and neuroretinitis. J Ophthalmic Inflamm Infect. 2016, 6:8. 10.1186\/s12348-016-0074-3","journal-title":"J Ophthalmic Inflamm Infect"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2006.11.014","article-title":"Idiopathic retinitis, vasculitis, aneurysms, and neuroretinitis (IRVAN): new observations and a proposed staging system","volume":"114","author":"Samuel MA","year":"2007","unstructured":"Samuel MA, Equi RA, Chang TS, Mieler W, Jampol LM, Hay D, Yannuzzi LA. Idiopathic retinitis, vasculitis, aneurysms, and neuroretinitis (IRVAN): new observations and a proposed staging system. Ophthalmology. 2007, 114:1526-9.e1. 10.1016\/j.ophtha.2006.11.014","journal-title":"Ophthalmology"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.amsu.2022.103725","article-title":"IRVAN syndrome: a case report and a literature review","volume":"77","author":"Mansour M","year":"2022","unstructured":"Mansour M, Al-Ghotani B, Abo-Shdeed B, Jannoud O. IRVAN syndrome: a case report and a literature review. Ann Med Surg (Lond). 2022, 77:103725. 10.1016\/j.amsu.2022.103725","journal-title":"Ann Med Surg (Lond)"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/0039-6257(88)90160-9","article-title":"Retinal arterial macroaneurysms","volume":"33","author":"Rabb MF","year":"1988","unstructured":"Rabb MF, Gagliano DA, Teske MP. Retinal arterial macroaneurysms. Surv Ophthalmol. 1988, 33:73-96. 10.1016\/0039-6257(88)90160-9","journal-title":"Surv Ophthalmol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1159\/000449122","article-title":"Long-term management of complications of retinal artery macroaneurysms with intravitreal aflibercept injection","volume":"7","author":"Kishore K","year":"2016","unstructured":"Kishore K. Long-term management of complications of retinal artery macroaneurysms with intravitreal aflibercept injection. Case Rep Ophthalmol. 2016, 7:162-71. 10.1159\/000449122","journal-title":"Case Rep Ophthalmol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-010-0378-2","article-title":"Expression of vascular endothelial growth factor receptor-1\/-2 and nitric oxide in unruptured intracranial aneurysms","volume":"31","author":"Maderna E","year":"2010","unstructured":"Maderna E, Corsini E, Franzini A, et al.. Expression of vascular endothelial growth factor receptor-1\/-2 and nitric oxide in unruptured intracranial aneurysms. Neurol Sci. 2010, 31:617-23. 10.1007\/s10072-010-0378-2","journal-title":"Neurol Sci"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1055\/s-0032-1328377","article-title":"Intravitreal anti-VEGF therapy for retinal macroaneurysm","volume":"230","author":"Zweifel SA","year":"2013","unstructured":"Zweifel SA, T\u00f6nz MS, Pfenninger L, Becker M, Michels S. Intravitreal anti-VEGF therapy for retinal macroaneurysm. Klin Monbl Augenheilkd. 2013, 230:392-5. 10.1055\/s-0032-1328377","journal-title":"Klin Monbl Augenheilkd"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/S0042-6989(96)00328-8","article-title":"Retinal ischemia leads to apoptosis which is ameliorated by aurintricarboxylic acid","volume":"37","author":"Rosenbaum DM","year":"1997","unstructured":"Rosenbaum DM, Rosenbaum PS, Gupta A, Michaelson MD, Hall DH, Kessler JA. Retinal ischemia leads to apoptosis which is ameliorated by aurintricarboxylic acid. Vision Res. 1997, 37:3445-51. 10.1016\/S0042-6989(96)00328-8","journal-title":"Vision Res"},{"key":"ref12","unstructured":"\u200bIntra-retinal microvascular abnormalities (IRMA). (2023). Accessed. March 6, 2023: https:\/\/www.optos.com\/recognizing-pathology\/definitions\/intra-retinal-microvascular-abnormalities-irma\/."},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s10456-011-9249-6","article-title":"Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab","volume":"15","author":"Papadopoulos N","year":"2012","unstructured":"Papadopoulos N, Martin J, Ruan Q, et al.. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis. 2012, 15:171-85. 10.1007\/s10456-011-9249-6","journal-title":"Angiogenesis"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajoc.2022.101289","article-title":"Intraocular inflammation secondary to intravitreal brolucizumab treated successfully with Sub-Tenon triamcinolone: a case report","volume":"25","author":"Kurup SK","year":"2022","unstructured":"Kurup SK, Tabbaa T, Echegaray JJ, Oliver AL. Intraocular inflammation secondary to intravitreal brolucizumab treated successfully with Sub-Tenon triamcinolone: a case report. Am J Ophthalmol Case Rep. 2022, 25:101289. 10.1016\/j.ajoc.2022.101289","journal-title":"Am J Ophthalmol Case Rep"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1414264","article-title":"Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema","volume":"372","author":"Wells JA","year":"2015","unstructured":"Wells JA, Glassman AR, Ayala AR, et al.. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med. 2015, 372:1193-203. 10.1056\/NEJMoa1414264","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1159\/000368794","article-title":"Management of macular edema secondary to branch retinal vein occlusion in an eye with prior vitrectomy and lensectomy","volume":"5","author":"Malhotra P","year":"2014","unstructured":"Malhotra P, Kishore K. Management of macular edema secondary to branch retinal vein occlusion in an eye with prior vitrectomy and lensectomy. Case Rep Ophthalmol. 2014, 5:335-42. 10.1159\/000368794","journal-title":"Case Rep Ophthalmol"},{"key":"ref17","article-title":"The multimodal imaging characteristics of IRVAN syndrome: a case report","volume":"13","author":"Lin X","year":"2021","unstructured":"Lin X, Meng Z, Deng A, Chen X, Wang S, Gu S, Li N. The multimodal imaging characteristics of IRVAN syndrome: a case report. Am J Transl Res. 2021, 13:9866-73.","journal-title":"Am J Transl Res"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/s10792-018-0917-z","article-title":"Further observations on a bilateral IRVAN syndrome case","volume":"39","author":"Rodr\u00edguez \u00c1","year":"2019","unstructured":"Rodr\u00edguez \u00c1, Carpio-Rosso W, Rodr\u00edguez FJ. Further observations on a bilateral IRVAN syndrome case. Int Ophthalmol. 2019, 39:1179-86. 10.1007\/s10792-018-0917-z","journal-title":"Int Ophthalmol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2020.1821902","article-title":"Extensive dynamics of aneurysms and Long-term prognosis in IRVAN syndrome: a case series","volume":"30","author":"Zhang Y","year":"2022","unstructured":"Zhang Y, Chang T, Ge G, Zhang M. Extensive dynamics of aneurysms and Long-term prognosis in IRVAN syndrome: a case series. Ocul Immunol Inflamm. 2022, 30:623-7. 10.1080\/09273948.2020.1821902","journal-title":"Ocul Immunol Inflamm"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/146291-aflibercept-for-the-treatment-of-macular-edema-secondary-to-idiopathic-retinal-vasculitis-aneurysms-and-neuroretinitis-syndrome","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:56:02Z","timestamp":1707508562000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/146291-aflibercept-for-the-treatment-of-macular-edema-secondary-to-idiopathic-retinal-vasculitis-aneurysms-and-neuroretinitis-syndrome"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,26]]},"references-count":19,"URL":"https:\/\/doi.org\/10.7759\/cureus.38154","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4,26]]}}}